Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones
December 20, 2018 08:00 ET
|
Pascal Biosciences Inc.
- 2018 pipeline expansion includes lead cannabinoid-based cancer therapeutic- Clinical trial in glioblastoma to begin in 2019 VANCOUVER, British Columbia and SEATTLE, Dec. 20, 2018 (GLOBE NEWSWIRE)...
Pascal Biosciences Announces Year-End Investor Update Webcast
December 10, 2018 20:45 ET
|
Pascal Biosciences Inc.
Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE...
Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs
November 28, 2018 08:00 ET
|
Pascal Biosciences Inc.
VANCOUVER, B.C. and SEATTLE, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the...
Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells
November 05, 2018 08:00 ET
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced...
Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer
October 30, 2018 08:00 ET
|
Pascal Biosciences Inc.
Program Developed in Lab of Renowned Cannabis Researcher Dr. Nephi Stella-Lead Candidate for Glioblastoma to Begin Clinical Testing in 2019 VANCOUVER, B.C. and SEATTLE, Oct. 30, 2018 (GLOBE...
Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors
July 16, 2018 09:00 ET
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, July 16, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the...
Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration
June 18, 2018 08:30 ET
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, June 18, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX-V:PAS) (Pascal), is pleased to announce significant progress in its cannabinoid based research and...
Pascal Announces Oversubscription of Financing
March 08, 2018 20:35 ET
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, March 08, 2018 (GLOBE NEWSWIRE) -- NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Pascal...
Pascal Biosciences Inc. Announces Non-Brokered Private Placement
February 23, 2018 11:14 ET
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) arranges a non-brokered private placement of up to 12,500,000 units...
Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells
February 21, 2018 09:30 ET
|
Pascal Biosciences Inc.
VANCOUVER, British Columbia and SEATTLE, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today announced the Company has discovered certain...